Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
ROA | = | 100 | × | Net income (loss)1 | ÷ | Total assets1 | |
---|---|---|---|---|---|---|---|
Dec 31, 2024 | = | 100 | × | ÷ | |||
Dec 31, 2023 | = | 100 | × | ÷ | |||
Dec 31, 2022 | = | 100 | × | ÷ | |||
Dec 31, 2021 | = | 100 | × | ÷ | |||
Dec 31, 2020 | = | 100 | × | ÷ | |||
Dec 31, 2019 | = | 100 | × | ÷ | |||
Dec 31, 2018 | = | 100 | × | ÷ | |||
Dec 31, 2017 | = | 100 | × | ÷ | |||
Dec 31, 2016 | = | 100 | × | ÷ | |||
Dec 31, 2015 | = | 100 | × | ÷ | |||
Dec 31, 2014 | = | 100 | × | ÷ | |||
Dec 31, 2013 | = | 100 | × | ÷ | |||
Dec 31, 2012 | = | 100 | × | ÷ | |||
Dec 31, 2011 | = | 100 | × | ÷ | |||
Dec 31, 2010 | = | 100 | × | ÷ | |||
Dec 31, 2009 | = | 100 | × | ÷ | |||
Dec 31, 2008 | = | 100 | × | ÷ | |||
Dec 31, 2007 | = | 100 | × | ÷ | |||
Dec 31, 2006 | = | 100 | × | ÷ | |||
Dec 31, 2005 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
The annual financial data reveals several notable trends in profitability, asset growth, and efficiency metrics over the assessed period.
- Net Income
- The net income demonstrates considerable variability over the years. Initially, it increased steadily from approximately $1.98 billion in 2005 to $2.95 billion in 2007. A significant negative dip occurred in 2008 with a loss of around $2.07 billion, followed by a strong recovery peaking at $8.32 billion in 2019. Subsequent years saw fluctuations with notable declines in 2014 and 2017, including another negative figure in 2017 at about -$204 million. An important surge is observed in 2024 with net income reaching $10.59 billion, the highest in the timeframe. Overall, net income exhibits periods of volatility but demonstrates strong growth potential and resilience.
- Total Assets
- Total assets grew overall, starting from approximately $24.58 billion in 2005 and showing a general upward trend, reaching $78.71 billion by 2024. Despite some fluctuations, such as a slight decrease between 2013 and 2015 and a temporary dip in 2019, the trend indicates substantial expansion in asset base over the period. This growth reflects ongoing investments and possible strategic acquisitions or capital expenditures.
- Return on Assets (ROA)
- ROA indicates profitability relative to asset size and exhibits notable fluctuations. It started at 8.05% in 2005 and peaked at 16.35% in 2010. A sharp negative return of -7.09% was recorded in 2008, corresponding with the net loss in that year, highlighting operational challenges. After recovery, ROA fluctuated mostly between 6% and 13%, with a dip to -0.45% in 2017, signaling another year of profitability pressure. The highest observed ROA was 21.17% in 2019, reflecting an exceptional efficiency in leveraging assets to generate earnings. The 2024 ROA of 13.45% shows a positive return despite increased asset base and heightened net income.
In summary, the data indicates a company with strong asset growth and varying profitability, including periods of losses and rebounds. The fluctuations in net income and ROA align, reflecting sensitivity to market or operational conditions. The recent years display significant improvement in both net income and ROA, suggesting enhanced operational efficiency and financial performance going forward.
Comparison to Competitors
Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | ||||||||||||
Dec 31, 2023 | ||||||||||||
Dec 31, 2022 | ||||||||||||
Dec 31, 2021 | ||||||||||||
Dec 31, 2020 | ||||||||||||
Dec 31, 2019 | ||||||||||||
Dec 31, 2018 | ||||||||||||
Dec 31, 2017 | ||||||||||||
Dec 31, 2016 | ||||||||||||
Dec 31, 2015 | ||||||||||||
Dec 31, 2014 | ||||||||||||
Dec 31, 2013 | ||||||||||||
Dec 31, 2012 | ||||||||||||
Dec 31, 2011 | ||||||||||||
Dec 31, 2010 | ||||||||||||
Dec 31, 2009 | ||||||||||||
Dec 31, 2008 | ||||||||||||
Dec 31, 2007 | ||||||||||||
Dec 31, 2006 | ||||||||||||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Eli Lilly & Co., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Eli Lilly & Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2024 | ||
Dec 31, 2023 | ||
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 | ||
Dec 31, 2012 | ||
Dec 31, 2011 | ||
Dec 31, 2010 | ||
Dec 31, 2009 | ||
Dec 31, 2008 | ||
Dec 31, 2007 | ||
Dec 31, 2006 | ||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Eli Lilly & Co. | Health Care | |
---|---|---|
Dec 31, 2024 | ||
Dec 31, 2023 | ||
Dec 31, 2022 | ||
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 | ||
Dec 31, 2012 | ||
Dec 31, 2011 | ||
Dec 31, 2010 | ||
Dec 31, 2009 | ||
Dec 31, 2008 | ||
Dec 31, 2007 | ||
Dec 31, 2006 | ||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).